ERIC J GRIGSBY
- Type
- Physician · Allopathic & Osteopathic Physicians / Pain Medicine / Pain Medicine
- Where
- NAPA, CA
- NPI
- 1952328494
- Received
- $564,238 in 84 records, 2019 to 2025 ($499,451 general, $64,786 research)
- As principal investigator
- $2,691,930 of research payments to others in 96 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 2 | $53 |
| 2024 | General payment | 6 | $313 |
| 2023 | General payment | 3 | $536 |
| 2023 | Research payment | 2 | $1,252 |
| 2022 | General payment | 3 | $120 |
| 2022 | Research payment | 2 | $15,494 |
| 2021 | General payment | 11 | $157,640 |
| 2021 | Research payment | 2 | $48,039 |
| 2020 | General payment | 6 | $144,379 |
| 2019 | General payment | 47 | $196,407 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| BIONESS INC | 5 | $448,930 | 2019–2021 |
| Eli Lilly and Company | 7 | $64,825 | 2021–2023 |
| Boston Scientific Corporation | 19 | $29,901 | 2019 |
| Biogen, Inc. | 13 | $12,288 | 2019–2020 |
| Medtronic, Inc. | 11 | $4,226 | 2021–2025 |
| Medtronic USA, Inc. | 7 | $2,407 | 2019–2020 |
| TerSera Therapeutics LLC | 7 | $465 | 2019–2020 |
| Saluda Medical Americas, Inc. | 1 | $375 | 2023 |
| Neuronetics, Inc. | 5 | $339 | 2021–2022 |
| Bioventus LLC | 2 | $200 | 2021 |
| Nevro Corp. | 3 | $106 | 2019–2020 |
| SPR Therapeutics, Inc | 1 | $73 | 2024 |
| Spinal Elements, Inc. | 1 | $48 | 2023 |
| Lilly USA, LLC | 1 | $26 | 2024 |
| Eisai Inc. | 1 | $21 | 2024 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Education | 6 | $446,428 |
| Research payment | 6 | $64,786 |
| Consulting Fee | 6 | $19,242 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 2 | $17,375 |
| Travel and Lodging | 13 | $6,826 |
| Grant | 2 | $4,390 |
| Entertainment | 2 | $2,678 |
| Food and Beverage | 47 | $2,510 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-06-18 | Medtronic, Inc. | $33 | Food and Beverage | In-kind items and services | SYNCHROMEDII Device, Drug Infusion Systems | 2025 | |
| 2025-02-21 | Medtronic, Inc. | $20 | Food and Beverage | In-kind items and services | INTELLIS ADAPTIVESTIM Device, Spinal Cord Neurostimulation | 2025 | |
| 2024-11-22 | Lilly USA, LLC | $26 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-09-18 | Medtronic, Inc. | $21 | Food and Beverage | In-kind items and services | SYNCHROMEDII Device, Drug Infusion Systems | 2024 | |
| 2024-08-26 | Medtronic, Inc. | $31 | Food and Beverage | In-kind items and services | INTELLIS ADAPTIVESTIM Device, Spinal Cord Neurostimulation | 2024 | |
| 2024-07-24 | Medtronic, Inc. | $139 | Food and Beverage | In-kind items and services | SYNCHROMEDII Device, Drug Infusion Systems | 2024 | |
| 2024-06-14 | Eisai Inc. | $21 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2024 | |
| 2024-02-03 | SPR Therapeutics, Inc | $73 | Food and Beverage | Cash or cash equivalent | SPRINT PNS System Device, Pain management | 2024 | |
| 2023-05-09 | Saluda Medical Americas, Inc. | $375 | Travel and Lodging | In-kind items and services | Evoke SCS Device, Spinal Cord Stimulation | 2023 | |
| 2023-03-08 | Eli Lilly and Company | $952 | Research payment | In-kind items and services | A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | 2023 | |
| 2023-02-03 | Spinal Elements, Inc. | $48 | Food and Beverage | Cash or cash equivalent | 2023 | ||
| 2023-01-31 | Eli Lilly and Company | $300 | Research payment | In-kind items and services | A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | 2023 | |
| 2023-01-12 | Medtronic, Inc. | $111 | Food and Beverage | In-kind items and services | INTELLIS ADAPTIVESTIM Device, Spinal Cord Neurostimulation | 2023 | |
| 2022-08-20 | Neuronetics, Inc. | $41 | Food and Beverage | Cash or cash equivalent | NEUROSTAR TMS THERAPY SYSTEM Device, NEUROSTAR TMS THERAPY SYSTEM | 2022 | |
| 2022-08-20 | Neuronetics, Inc. | $41 | Food and Beverage | Cash or cash equivalent | NEUROSTAR TMS THERAPY SYSTEM Device, NEUROSTAR TMS THERAPY SYSTEM | 2022 | |
| 2022-06-27 | Eli Lilly and Company | $38 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-02-01 | Eli Lilly and Company | $6,882 | Research payment | In-kind items and services | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2022 | |
| 2022-01-21 | Eli Lilly and Company | $8,612 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2022 | |
| 2021-11-16 | Medtronic, Inc. | $24 | Food and Beverage | In-kind items and services | ASCENDA Device, Drug Infusion Systems | 2021 | |
| 2021-08-28 | Neuronetics, Inc. | $74 | Food and Beverage | Cash or cash equivalent | NEUROSTAR TMS THERAPY Device, NEUROSTAR TMS THERAPY | 2021 | |
| 2021-08-28 | Neuronetics, Inc. | $31 | Food and Beverage | Cash or cash equivalent | NEUROSTAR TMS THERAPY Device, NEUROSTAR TMS THERAPY | 2021 | |
| 2021-08-12 | Neuronetics, Inc. | $151 | Food and Beverage | Cash or cash equivalent | NEUROSTAR TMS THERAPY Device, NEUROSTAR TMS THERAPY | 2021 | |
| 2021-07-20 | Eli Lilly and Company | $40,486 | Research payment | Cash or cash equivalent | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2021 | |
| 2021-05-04 | Bioventus LLC | $63 | Food and Beverage | In-kind items and services | Stimrouter Implantable Kit Device, Podiatry | 2021 | |
| 2021-05-03 | Medtronic, Inc. | $9 | Food and Beverage | In-kind items and services | SYNCHROMED Device, Drug Infusion Systems | 2021 | |
| 2021-04-14 | Bioventus LLC | $137 | Food and Beverage | In-kind items and services | Stimrouter Implantable Kit Device, Podiatry | 2021 | |
| 2021-04-12 | Eli Lilly and Company | $7,553 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2021 | |
| 2021-03-15 | Medtronic, Inc. | $10 | Food and Beverage | In-kind items and services | SYNCHROMED Device, Drug Infusion Systems | 2021 | |
| 2021-02-17 | Medtronic, Inc. | $2,040 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-02-17 | Medtronic, Inc. | $1,785 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-01-11 | BIONESS INC | $153,313 | Education (14 payments) | Cash or cash equivalent | StimRouter for pain Device, Implant | 2021 | |
| 2020-03-09 | TerSera Therapeutics LLC | $60 | Education | In-kind items and services | PRIALT Drug, PAIN | 2020 | |
| 2020-03-05 | Biogen, Inc. | $2,295 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-02-12 | Nevro Corp. | $46 | Food and Beverage | In-kind items and services | Senza Spinal Cord Stimulation System Device, Spinal Cord Stimulator | 2020 | |
| 2020-01-31 | BIONESS INC | $140,852 | Education (12 payments) | Cash or cash equivalent | Stimrouter for Pain Device, Implant | 2020 | |
| 2020-01-24 | Medtronic USA, Inc. | $41 | Food and Beverage | In-kind items and services | 2020 | ||
| 2020-01-22 | BIONESS INC | $1,083 | Entertainment (6 payments) | In-kind items and services | Stimrouter for Pain Device, Implant | 2020 | |
| 2019-12-12 | TerSera Therapeutics LLC | $41 | Food and Beverage | In-kind items and services | PRIALT Drug, PAIN | 2019 | |
| 2019-10-24 | Medtronic USA, Inc. | $2,167 | Consulting Fee | Cash or cash equivalent | AUTOFILL Device, Spinal Cord Neurostimulation | 2019 | |
| 2019-10-24 | Medtronic USA, Inc. | $8 | Food and Beverage | In-kind items and services | TARGETSTIM Device, Spinal Cord Neurostimulation | 2019 | |
| 2019-10-13 | Nevro Corp. | $32 | Food and Beverage | In-kind items and services | Senza Spinal Cord Stimulation System Device, Spinal Cord Stimulator | 2019 | |
| 2019-10-03 | Medtronic USA, Inc. | $20 | Food and Beverage | In-kind items and services | VECTRIS Device, Spinal Cord Neurostimulation | 2019 | |
| 2019-08-21 | Boston Scientific Corporation | $550 | Consulting Fee | Cash or cash equivalent | SPECTRA WAVEWRITER Device, PAIN MANAGEMENT | 2019 | |
| 2019-07-17 | Boston Scientific Corporation | $35 | Food and Beverage | In-kind items and services | SPECTRA WAVEWRITER Device, PAIN MANAGEMENT | 2019 | |
| 2019-06-11 | Biogen, Inc. | $5,550 | Consulting Fee | Cash or cash equivalent | SPINRAZA Biological, NEUROLOGY | 2019 | |
| 2019-06-05 | Boston Scientific Corporation | $7,150 | Consulting Fee | Cash or cash equivalent | SPECTRA WAVEWRITER Device, PAIN MANAGEMENT | 2019 | |
| 2019-06-05 | Boston Scientific Corporation | $6,875 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SPECTRA WAVEWRITER Device, PAIN MANAGEMENT | 2019 | |
| 2019-06-05 | Boston Scientific Corporation | $540 | Travel and Lodging | Cash or cash equivalent | SPECTRA WAVEWRITER Device, PAIN MANAGEMENT | 2019 | |
| 2019-06-05 | Boston Scientific Corporation | $413 | Travel and Lodging | Cash or cash equivalent | SPECTRA WAVEWRITER Device, PAIN MANAGEMENT | 2019 | |
| 2019-06-05 | Boston Scientific Corporation | $114 | Food and Beverage | Cash or cash equivalent | SPECTRA WAVEWRITER Device, PAIN MANAGEMENT | 2019 | |
| 2019-06-05 | Boston Scientific Corporation | $19 | Food and Beverage | Cash or cash equivalent | SPECTRA WAVEWRITER Device, PAIN MANAGEMENT | 2019 | |
| 2019-06-01 | Biogen, Inc. | $400 | Travel and Lodging | Cash or cash equivalent | SPINRAZA Biological, NEUROLOGY | 2019 | |
| 2019-06-01 | Biogen, Inc. | $63 | Food and Beverage | Cash or cash equivalent | SPINRAZA Biological, NEUROLOGY | 2019 | |
| 2019-06-01 | Biogen, Inc. | $58 | Food and Beverage | Cash or cash equivalent | SPINRAZA Biological, NEUROLOGY | 2019 | |
| 2019-06-01 | Biogen, Inc. | $44 | Food and Beverage | Cash or cash equivalent | SPINRAZA Biological, NEUROLOGY | 2019 | |
| 2019-05-31 | Biogen, Inc. | $1,131 | Travel and Lodging | Cash or cash equivalent | SPINRAZA Biological, NEUROLOGY | 2019 | |
| 2019-05-31 | Biogen, Inc. | $358 | Travel and Lodging | Cash or cash equivalent | SPINRAZA Biological, NEUROLOGY | 2019 | |
| 2019-05-31 | Biogen, Inc. | $124 | Food and Beverage | Cash or cash equivalent | SPINRAZA Biological, NEUROLOGY | 2019 | |
| 2019-05-31 | Biogen, Inc. | $49 | Food and Beverage | In-kind items and services | SPINRAZA Biological, NEUROLOGY | 2019 | |
| 2019-05-14 | Medtronic USA, Inc. | $106 | Food and Beverage | In-kind items and services | TARGETSTIM Device, Spinal Cord Neurostimulation | 2019 | |
| 2019-05-14 | Biogen, Inc. | $66 | Education | In-kind items and services | SPINRAZA Biological, NEUROLOGY | 2019 | |
| 2019-05-14 | Biogen, Inc. | $49 | Education | In-kind items and services | SPINRAZA Biological, NEUROLOGY | 2019 | |
| 2019-05-11 | TerSera Therapeutics LLC | $86 | Food and Beverage | In-kind items and services | PRIALT Drug, PAIN | 2019 | |
| 2019-05-09 | TerSera Therapeutics LLC | $98 | Food and Beverage | In-kind items and services | PRIALT Drug, PAIN | 2019 | |
| 2019-05-09 | TerSera Therapeutics LLC | $86 | Food and Beverage | In-kind items and services | PRIALT Drug, PAIN | 2019 | |
| 2019-05-09 | TerSera Therapeutics LLC | $55 | Food and Beverage | In-kind items and services | PRIALT Drug, PAIN | 2019 | |
| 2019-05-08 | TerSera Therapeutics LLC | $35 | Food and Beverage | In-kind items and services | ZOLADEX Drug, ONCOLOGY | 2019 | |
| 2019-05-05 | Boston Scientific Corporation | $1,197 | Travel and Lodging | In-kind items and services | GENERAL THERAPIES Device, GENERAL THERAPIES | 2019 | |
| 2019-05-03 | Boston Scientific Corporation | $13 | Food and Beverage | In-kind items and services | SPECTRA WAVEWRITER Device, PAIN MANAGEMENT | 2019 | |
| 2019-05-02 | Boston Scientific Corporation | $10 | Food and Beverage | In-kind items and services | SPECTRA WAVEWRITER Device, PAIN MANAGEMENT | 2019 | |
| 2019-05-01 | Boston Scientific Corporation | $335 | Travel and Lodging | In-kind items and services | GENERAL THERAPIES Device, GENERAL THERAPIES | 2019 | |
| 2019-05-01 | Boston Scientific Corporation | $213 | Travel and Lodging | In-kind items and services | GENERAL THERAPIES Device, GENERAL THERAPIES | 2019 | |
| 2019-04-24 | Boston Scientific Corporation | $10,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SPECTRA WAVEWRITER Device, PAIN MANAGEMENT | 2019 | |
| 2019-04-24 | Boston Scientific Corporation | $1,454 | Travel and Lodging | Cash or cash equivalent | SPECTRA WAVEWRITER Device, PAIN MANAGEMENT | 2019 | |
| 2019-04-24 | Boston Scientific Corporation | $212 | Travel and Lodging | Cash or cash equivalent | SPECTRA WAVEWRITER Device, PAIN MANAGEMENT | 2019 | |
| 2019-04-24 | Boston Scientific Corporation | $73 | Food and Beverage | Cash or cash equivalent | SPECTRA WAVEWRITER Device, PAIN MANAGEMENT | 2019 | |
| 2019-04-15 | Medtronic USA, Inc. | $48 | Food and Beverage | In-kind items and services | RESTORE Device, Spinal Cord Neurostimulation | 2019 | |
| 2019-03-21 | Biogen, Inc. | $2,095 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-02-28 | Nevro Corp. | $27 | Food and Beverage | In-kind items and services | Senza Spinal Cord Stimulation System Device, Spinal Cord Stimulator | 2019 | |
| 2019-01-20 | Boston Scientific Corporation | $82 | Travel and Lodging | In-kind items and services | SPECTRA WAVEWRITER Device, PAIN MANAGEMENT | 2019 | |
| 2019-01-18 | BIONESS INC | $1,594 | Entertainment (15 payments) | In-kind items and services | Stimrouter for pain Device, Implant | 2019 | |
| 2019-01-17 | Medtronic USA, Inc. | $15 | Food and Beverage | In-kind items and services | SYNERGY Device, Spinal Cord Neurostimulation | 2019 | |
| 2019-01-15 | Boston Scientific Corporation | $112 | Travel and Lodging | In-kind items and services | SPECTRA WAVEWRITER Device, PAIN MANAGEMENT | 2019 | |
| 2019-01-07 | BIONESS INC | $152,086 | Education (17 payments) | Cash or cash equivalent | Stimrouter for pain Device, Implant | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-11-17 | Medtronic, Inc. | Napa Biomedical Services Inc. | $626 | PSR-TDD | 2025 |
| 2025-08-15 | Medtronic, Inc. | Napa Biomedical Services Inc. | $14,845 | PSR-TDD | 2025 |
| 2025-08-15 | Medtronic, Inc. | Napa Biomedical Services Inc. | $939 | PSR-PSTM | 2025 |
| 2025-07-28 | Amgen Inc. | NEUROVATIONS | $3,094 | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Parti | 2025 |
| 2025-05-16 | Medtronic, Inc. | Napa Biomedical Services Inc. | $4,593 | PSR-TDD | 2025 |
| 2025-05-16 | Medtronic, Inc. | Napa Biomedical Services Inc. | $8,879 | PSR-PSTM | 2025 |
| 2025-04-23 | E.R. Squibb & Sons, L.L.C. | Napa Surgery Center | $264 | A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-9 | 2025 |
| 2025-04-01 | Amgen Inc. | NAPA BIOMEDICAL NEUROVATIONS | $188,672 | A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Particip | 2025 |
| 2025-03-12 | Amgen Inc. | NEUROVATIONS RESEARCH | $16,905 | A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Particip | 2025 |
| 2025-03-03 | Eli Lilly and Company | NAPA BIOMEDICAL SERVICES INC DBA NEUROVATIONS | $10,750 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2025 |
| 2025-02-13 | Medtronic, Inc. | Napa Biomedical Services Inc. | $12,044 | PSR-TDD | 2025 |
| 2025-02-13 | Medtronic, Inc. | Napa Biomedical Services Inc. | $2,416 | PSR-PSTM | 2025 |
| 2025-02-10 | Eli Lilly and Company | NAPA BIOMEDICAL SERVICES INC DBA NEUROVATIONS | $5,068 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2025 |
| 2025-01-27 | Amgen Inc. | NEUROVATIONS | $19,282 | A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Particip | 2025 |
| 2025-01-21 | E.R. Squibb & Sons, L.L.C. | Napa Surgery Center | $14,403 | A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-9 | 2025 |
| 2025-01-15 | Amgen Inc. | NEUROVATIONS RESEARCH | $13,650 | P2 HZN-1116-201 Sjogren's Syndrome (SS) | 2025 |
| 2025-01-07 | Eli Lilly and Company | NAPA BIOMEDICAL SERVICES INC DBA NEUROVATIONS | $80,387 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2025 |
| 2024-11-07 | Medtronic, Inc. | NEUROVATIONS | $26,670 | PSR-TDD | 2024 |
| 2024-11-07 | Medtronic, Inc. | NEUROVATIONS | $6,952 | PSR-PSTM | 2024 |
| 2024-09-25 | E.R. Squibb & Sons, L.L.C. | Advarra Inc. | $170 | Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Partici | 2024 |
| 2024-08-16 | Amgen Inc. | NAPA BIOMEDICAL NEUROVATIONS | $41,175 | P2 HZN-1116-201 Sjogren's Syndrome SS | 2024 |
| 2024-08-15 | Medtronic, Inc. | NEUROVATIONS | $11,234 | PSR-PSTM | 2024 |
| 2024-08-15 | Medtronic, Inc. | NEUROVATIONS | $26,137 | PSR-TDD | 2024 |
| 2024-08-05 | Amgen Inc. | NEUROVATIONS | $8,638 | P2 HZN-1116-201 Sjogren's Syndrome SS | 2024 |
| 2024-07-25 | E.R. Squibb & Sons, L.L.C. | Napa Surgery Center | $19,978 | Phase 2 PoC in Early AD Patients - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy | 2024 |
| 2024-03-29 | E.R. Squibb & Sons, L.L.C. | Advarra Dba Schulman Associates Irb | $18,537 | Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Partici | 2024 |
| 2024-03-08 | Eli Lilly and Company | NAPA BIOMEDICAL SERVICES INC DBA NEUROVATIONS | $401 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2024 |
| 2024-02-14 | Medtronic, Inc. | NEUROVATIONS | $8,739 | PSR-TDD | 2024 |
| 2024-02-14 | Medtronic, Inc. | NEUROVATIONS | $1,677 | PSR-PSTM | 2024 |
| 2024-02-13 | Eli Lilly and Company | NAPA BIOMEDICAL SERVICES INC DBA NEUROVATIONS | $80,714 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2024 |
| 2024-01-25 | Eli Lilly and Company | NAPA BIOMEDICAL SERVICES INC DBA NEUROVATIONS | $1,954 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2024 |
| 2024-01-09 | Eli Lilly and Company | NAPA BIOMEDICAL SERVICES INC DBA NEUROVATIONS | $17,776 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2024 |
| 2024-01-09 | Novartis Pharmaceuticals Corporation | NEUROVATIONS | $123 | A 5-year, Randomized, Double-blind, Placebo-controlled, Multi-center Study Assessing the Efficacy, Safety, and Tolerabil | 2024 |
| 2023-11-09 | Medtronic, Inc. | NEUROVATIONS | $4,747 | PSR-TDD | 2023 |
| 2023-11-09 | Medtronic, Inc. | NEUROVATIONS | $808 | PSR-PSTM | 2023 |
| 2023-08-17 | Medtronic, Inc. | NEUROVATIONS | $91 | PSR-PSTM | 2023 |
| 2023-08-17 | Medtronic, Inc. | NEUROVATIONS | $3,898 | PSR-TDD | 2023 |
| 2023-08-03 | Medtronic, Inc. | NEUROVATIONS | $250 | PSR-PSTM | 2023 |
| 2023-08-03 | Medtronic, Inc. | NEUROVATIONS | $250 | PSR-TDD | 2023 |
| 2023-07-11 | Eli Lilly and Company | NAPA BIOMEDICAL SERVICES INC DBA NEUROVATIONS | $1,165 | A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | 2023 |
| 2023-05-15 | Medtronic, Inc. | NEUROVATIONS | $1,757 | PSR-PSTM | 2023 |
| 2023-05-15 | Medtronic, Inc. | NEUROVATIONS | $6,067 | PSR-TDD | 2023 |
| 2023-03-08 | Novartis Pharmaceuticals Corporation | NEUROVATIONS | $930 | A 5-year, Randomized, Double-blind, Placebo-controlled, Multi-center Study Assessing the Efficacy, Safety, and Tolerabil | 2023 |
| 2023-02-09 | Medtronic, Inc. | NEUROVATIONS | $4,881 | PSR-PSTM | 2023 |
| 2023-02-09 | Medtronic, Inc. | NEUROVATIONS | $5,877 | PSR-TDD | 2023 |
| 2023-01-26 | Eli Lilly and Company | NAPA BIOMEDICAL SERVICES INC DBA NEUROVATIONS | $2,701 | A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | 2023 |
| 2023-01-09 | Eli Lilly and Company | NAPA BIOMEDICAL SERVICES INC DBA NEUROVATIONS | $300,339 | A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | 2023 |
| 2023-01-09 | Eli Lilly and Company | NAPA BIOMEDICAL SERVICES INC DBA NEUROVATIONS | $93,320 | A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | 2023 |
| 2022-11-15 | Medtronic, Inc. | NEUROVATIONS | $11,845 | PSR-TDD | 2022 |
| 2022-11-15 | Medtronic, Inc. | NEUROVATIONS | $404 | PSR-PSTM | 2022 |
| 2022-09-27 | Eli Lilly and Company | NAPA BIOMEDICAL SERVICES INC DBA NEUROVATIONS | $22 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2022 |
| 2022-08-11 | Medtronic, Inc. | NEUROVATIONS | $3,474 | PSR-PSTM | 2022 |
| 2022-08-11 | Medtronic, Inc. | NEUROVATIONS | $9,207 | PSR-TDD | 2022 |
| 2022-07-26 | Eli Lilly and Company | NAPA BIOMEDICAL SERVICES INC DBA NEUROVATIONS | $78,796 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2022 |
| 2022-05-12 | Medtronic, Inc. | NEUROVATIONS | $18,373 | PSR-TDD | 2022 |
| 2022-05-12 | Medtronic, Inc. | NEUROVATIONS | $4,487 | PSR-PSTM | 2022 |
| 2022-03-31 | Neuronetics, Inc. | NEUROVATIONS | $45,000 | Chronic Comorbid Pain Study Milestone 1 | 2022 |
| 2022-02-16 | Medtronic, Inc. | NEUROVATIONS | $33,549 | PSR-TDD | 2022 |
| 2022-02-16 | Medtronic, Inc. | NEUROVATIONS | $4,215 | PSR-PSTM | 2022 |
| 2022-02-08 | Novartis Pharmaceuticals Corporation | NEUROVATIONS | $11,870 | A 5-YEAR, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY ASSESSING THE EFFICACY, SAFETY, AND TOLERABIL | 2022 |
| 2022-01-11 | Eli Lilly and Company | NAPA BIOMEDICAL SERVICES INC DBA NEUROVATIONS | $604,867 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2022 |
| 2021-12-09 | SEIKAGAKU CORPORATION | NEUROVATIONS | $2,700 | 6603/1133 | 2021 |
| 2021-11-11 | Medtronic, Inc. | NEUROVATIONS | $14,834 | PSR-PSTM | 2021 |
| 2021-11-11 | Medtronic, Inc. | NEUROVATIONS | $43,705 | PSR-TDD | 2021 |
| 2021-11-01 | Eli Lilly and Company | NAPA BIOMEDICAL SERVICES INC DBA NEUROVATIONS | $320,301 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2021 |
| 2021-08-16 | Medtronic, Inc. | NEUROVATIONS | $20,364 | PSR-TDD | 2021 |
| 2021-08-16 | Medtronic, Inc. | NEUROVATIONS | $4,154 | PSR-PSTM | 2021 |
| 2021-07-17 | SEIKAGAKU CORPORATION | NEUROVATIONS | $6,550 | 6603/1133 | 2021 |
| 2021-06-02 | SEIKAGAKU CORPORATION | NEUROVATIONS | $5,835 | 6603/1133 | 2021 |
| 2021-06-01 | Medtronic, Inc. | NEUROVATIONS | $14,578 | PSR-TDD | 2021 |
| 2021-06-01 | Medtronic, Inc. | NEUROVATIONS | $5,400 | PSR-PSTM | 2021 |
| 2021-05-27 | Medtronic, Inc. | NEUROVATIONS | $5,200 | Painful Diabetic Neuropathy | 2021 |
| 2021-04-30 | Medtronic, Inc. | NEUROVATIONS | $650 | Painful Diabetic Neuropathy | 2021 |
| 2021-03-11 | Medtronic, Inc. | NEUROVATIONS | $5,362 | Painful Diabetic Neuropathy | 2021 |
| 2021-03-02 | Medtronic, Inc. | NEUROVATIONS | $11,166 | PSR-PSTM | 2021 |
| 2021-03-02 | Medtronic, Inc. | NEUROVATIONS | $19,844 | PSR-TDD | 2021 |
| 2020-12-02 | Medtronic, Inc. | NEUROVATIONS | $19,230 | PSR-TDD | 2020 |
| 2020-12-02 | Medtronic, Inc. | NEUROVATIONS | $5,600 | PSR-PSTM | 2020 |
| 2020-08-20 | Medtronic, Inc. | NEUROVATIONS | $17,483 | PSR-TDD | 2020 |
| 2020-08-20 | Medtronic, Inc. | NEUROVATIONS | $3,941 | PSR-PSTM | 2020 |
| 2020-06-01 | Medtronic, Inc. | NEUROVATIONS | $43,054 | PSR-TDD | 2020 |
| 2020-06-01 | Medtronic, Inc. | NEUROVATIONS | $10,851 | PSR-PSTM | 2020 |
| 2020-02-27 | Medtronic, Inc. | NEUROVATIONS | $10,401 | PSR-TDD | 2020 |
| 2020-02-27 | Medtronic, Inc. | NEUROVATIONS | $3,080 | PSR-PSTM | 2020 |
| 2020-01-31 | Medtronic, Inc. | NEUROVATIONS | $250 | PSR-TDD | 2020 |
| 2020-01-31 | Medtronic, Inc. | NEUROVATIONS | $250 | PSR-PSTM | 2020 |
| 2019-11-18 | Medtronic, Inc. | Napa Biomedical Services Neurovations | $22,356 | PSR-TDD | 2019 |
| 2019-11-18 | Medtronic, Inc. | Napa Biomedical Services Neurovations | $4,740 | PSR-PSTM | 2019 |
| 2019-08-14 | Medtronic, Inc. | Napa Biomedical Services Neurovations | $37,425 | PSR-TDD | 2019 |
| 2019-08-14 | Medtronic, Inc. | Napa Biomedical Services Neurovations | $10,309 | PSR-PSTM | 2019 |
| 2019-07-16 | Medtronic, Inc. | Napa Biomedical Services Neurovations | $250 | PSR-TDD | 2019 |
| 2019-07-16 | Medtronic, Inc. | Napa Biomedical Services Neurovations | $250 | PSR-PSTM | 2019 |
| 2019-05-16 | Medtronic, Inc. | Napa Biomedical Services Neurovations | $62,375 | PSR-TDD | 2019 |
| 2019-05-16 | Medtronic, Inc. | Napa Biomedical Services Neurovations | $12,026 | PSR-PSTM | 2019 |
| 2019-02-18 | Medtronic, Inc. | Napa Biomedical Services Neurovations | $19,789 | PSR-TDD | 2019 |
| 2019-02-18 | Medtronic, Inc. | Napa Biomedical Services Neurovations | $6,737 | PSR-PSTM | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Napa, CA, county Napa County, CA, state California; placed by its city name.
| Measure | Place (city or town) Napa, CA | County Napa County, CA | State California |
|---|---|---|---|
| Population B01003 | 78,239 | 134,869 | 39,287,377 |
| Population, 2020 census P1 | 79,246 | 138,019 | 39,538,223 |
| Median age B01002 | 41.5 | 42.9 | 37.9 |
| Under 18 B01001 | 20.0% | 19.4% | 22.0% |
| 65 and over B01001 | 18.9% | 21.1% | 15.7% |
| Households B11001 | 29,984 | 49,763 | 13,548,091 |
| Foreign born B05002 | 20.9% | 22.2% | 27.0% |
| Median household income B19013 | $105,963 | $111,471 | $99,122 |
| Median family income B19113 | $131,663 | $137,457 | $113,346 |
| Per capita income B19301 | $56,032 | $61,040 | $49,513 |
| Poverty rate B17001 | 8.5% | 8.5% | 12.0% |
| Unemployment rate B23025 | 5.7% | 5.2% | 6.6% |
| Civilian labor force B23025 | 42,090 | 71,043 | 20,068,466 |
| Mean commute (minutes) B08013 | 23.9 | 24.9 | 28.7 |
| Bachelor's degree or higher B15003 | 38.2% | 39.8% | 37.1% |
| Housing units B25001 | 32,141 | 55,817 | 14,644,735 |
| Owner-occupied B25003 | 58.7% | 63.4% | 55.9% |
| Renters B25003 | 41.3% | 36.6% | 44.1% |
| Median home value B25077 | $856,400 | $869,500 | $734,700 |
| Median gross rent B25064 | $2,282 | $2,237 | $2,036 |
| White, not Hispanic B03002 | 50.3% | 48.6% | 33.8% |
| Black B03002 | 1.0% | 1.7% | 5.2% |
| Hispanic or Latino B03002 | 41.2% | 36.4% | 40.2% |
| Asian B03002 | 3.0% | 8.1% | 15.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Napa, CA.
Comments